

The Younger Patients Have More Better Prognosis in Limited Disease Small Cell Lung Cancer

Hye-Jin Kim, M.D.¹, Chang-Min Choi, M.D., Ph.D.^{2,3} and Seul-Gi Kim⁴

Departments of ¹Internal Medicine, ²Pulmonary and Critical Care Medicine, ³Oncology, and ⁴Biostatistical and Clinical Epidemiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Background: Factors associated with the prognosis of patients with small cell lung cancer (SCLC) is relatively unknown, than of those with non-small cell lung cancer. This study was undertaken to identify the prognostic factors of SCLC.

Methods: The medical records of 333 patients diagnosed with SCLC at tertiary hospital from January 1, 2008, to December 31, 2012 were retrospectively reviewed. Patients were categorized by age (≤ 65 years vs. >65 years) and by extent of disease (limited disease [LD] vs extensive disease [ED]). Overall survival and progression free survival rates were determined. Factors associated with prognosis were calculated using Cox's proportional hazard regression model.

Results: Most baseline characteristics were similar in the LD and ED groups. Eastern Cooperative Oncology Group (ECOG) performance status (PS), first chemotherapy regimen, and prophylactic cranial irradiation (PCI) differed significantly in patients with LD and ED. Mean ECOG PS was significantly lower ($p < 0.001$), first-line chemotherapy with etoposide-cisplatin was more frequent than with etoposide-carboplatin ($p < 0.001$), and PCI was performed more frequently ($p = 0.019$) in LD-SCLC than in ED-SCLC. Prognosis in the LD group was better in younger (≤ 65 years) than in older (>65 years) patients, but prognosis in the ED group was unrelated to age.

Conclusion: This study showed that overall survival (OS) was significantly improved in younger than in older patients with LD-SCLC. Univariate and multivariate analyses showed that age, PCI and the sum of cycles were significant predictors of OS in patients with LD-SCLC. However, prognosis in the ED group was unrelated to age.

Keywords: Prognosis; Small Cell lung Carcinoma; Age Groups

Introduction

Lung cancer is one of the most common forms of cancer worldwide. Patients with this disease have a bad prognosis. The main risk factor of lung cancer is smoking. It can be divided into two major types, non-small cell lung cancer and small cell lung cancer (SCLC)¹.

The prevalence of SCLC increases with age. At diagnosis, patients with SCLC can be subdivided into those with limited disease (LD) and extensive disease (ED). Multimorbid conditions have been associated with a slightly increased hazard of death in patients with LD-SCLC, independent of treatment². By contrast, the prognosis in patients with ED-SCLC is associated with treatment, not with age².

This study was designed to determine the prognostic factors affecting survival in patients with SCLC, who were diagnosed with this disease at Asan Medical Center from January 1, 2008, to December 31, 2012.

Address for correspondence: Chang-Min Choi, M.D., Ph.D.

Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea

Phone: 82-2-3010-5902, **Fax:** 82-2-3010-6968

E-mail: ccm@amc.seoul.kr

Received: Mar. 8, 2016

Revised: May. 8, 2016

Accepted: Jun. 22, 2016

© It is identical to the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>).



Copyright © 2016
The Korean Academy of Tuberculosis and Respiratory Diseases.
All rights reserved.

Table 1. Baseline characteristics

Variable	Total	LD (n=198)	ED (n=135)	p-value
Age, yr				0.488
≤65	165 (49.5)	95 (48.0)	70 (51.9)	
>65	168 (50.5)	103 (52.0)	65 (48.1)	
BMI, kg/m ²				0.767
≤23	162 (48.6)	95 (48.0)	67 (49.6)	
>23	171 (51.4)	103 (52.0)	68 (50.4)	
ECOG PS				<0.001
0, 1	239 (71.8)	176 (88.9)	63 (46.7)	
2	94 (28.2)	22 (11.1)	72 (53.3)	
Smoking				0.643
Current or ex-smoker	285 (86)	168 (85)	117 (87)	
Non-smoker	48 (14)		18 (13)	
Smoking (PY)	40.0 (30.0–50.0)	40.0 (28.0–50.0)	42.5 (30.0–50.0)	0.152
Comorbidity				
DM	55 (16.5)	31 (15.7)	24 (17.8)	0.609
HF	1 (0.3)	1 (0.5)	0 (0)	>0.999*
CRF	0 (0)	0 (0)	0 (0)	
LC	2 (0.6)	1 (0.5)	1 (0.7)	>0.999*
CVA	8 (2.4)	7 (3.5)	1 (0.7)	0.149*
Inactive TB	32 (9.6)	16 (8.1)	16 (11.9)	0.252
First CTx regimen				<0.001
EP	257 (77.2)	179 (90.4)	78 (57.8)	
EC	76 (22.8)	19 (9.6)	57 (42.2)	
The sum of cycles				0.099
2–3	48 (14.4)	22 (11.1)	26 (19.3)	
≥4	285 (85.6)	176 (88.9)	109 (80.7)	
Thoracic RT (CCRT)				0.053
Yes	209 (62.8)	177 (89.4)	32 (23.7)	
No	123 (37.2)	21 (10.6)	102 (76.3)	
PCI				0.019
Yes	113 (33.9)	77 (38.9)	36 (26.7)	
No	222 (66.1)	121 (61.1)	101 (73.3)	
Progression of disease				0.022
Progression	56 (16.8)	41 (20.7)	15 (11.1)	
Non-progression	277 (83.2)	157 (79.3)	120 (88.9)	
Cause of death				<0.001
Progression	137 (80.1)	28 (52.8)	109 (92.4)	
Else	34 (9.9)	25 (47.2)	9 (7.6)	

Values are presented as number (%).

*Using Fisher exact test.

LD: limited disease; ED: extensive disease; BMI: body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status; PY: pack years; DM: diabetes mellitus; HF: heart failure; CRF: chronic renal failure; LC: liver cirrhosis; CVA: cerebrovascular disease; TB: tuberculosis; CTx: chemotherapy; EP: etoposide-cisplatin; EC: etoposide-carboplatin; RT: radiotherapy; CCRT: concurrent chemoradiotherapy; PCI: prophylactic cranial irradiation.

Materials and Methods

December 31, 2012.

1. Patient selection

This study included 333 patients who were newly diagnosed with SCLC at tertiary hospital from January 1, 2008, to

2. Study design

Patient records were compiled and analyzed retrospectively using the ABLE^{3,4} (Asan Biomedical Research Environment)

Table 2. Baseline characteristics (limited disease small cell lung cancer)

Variable	Total	≤65 Years (n=95)	>65 Years (n=103)	p-value
BMI, kg/m ²				0.006
≤23	95 (48.0)	36 (37.9)	59 (57.3)	
>23	103 (52.0)	59 (62.1)	44 (42.7)	
ECOG PS				0.360
0, 1	177 (89.3)	83 (87.4)	94 (91.3)	
2	21 (10.7)	12 (12.6)	9 (8.7)	
Smoking				0.178
Current or ex-smoker	168 (84.8)	84 (88.4)	84 (81.6)	
Non-smoker	30 (15.2)	11 (11.6)	19 (18.4)	
Smoking (PY)	40.0 (30.0–53.0)	40.0 (23.0–47.5)	45.0 (30.0–60.0)	0.003
Comorbidity				
DM	31 (15.7)	16 (16.8)	15 (14.6)	0.659
HF	1 (0.5)	0 (0)	1 (1.0)	>0.999*
CRF	0 (0)	0 (0)	0 (0)	
LC	1 (0.5)	1 (1.1)	0 (0)	0.480*
CVA	7 (3.5)	2 (2.1)	5 (4.9)	0.447*
Inactive TB	16 (8.1)	8 (8.4)	8 (7.8)	0.866
First CTx regimen				0.003
EP	179 (90.4)	92 (96.8)	87 (84.5)	
EC	19 (9.6)	3 (3.2)	16 (15.5)	
The sum of cycles				0.303
2–3	22 (11.1)	7 (7.4)	15 (14.6)	
≥4	176 (88.9)	88 (92.6)	88 (85.4)	
Thoracic RT (CCRT)				0.338
Yes	177 (89.4)	87 (91.6)	90 (87.4)	
PCI				0.002
Yes	77 (38.9)	48 (50.5)	29 (28.2)	
Progression of disease				0.641
Progression	41 (20.7)	21 (22.1)	20 (19.4)	
Non-progression	157 (79.3)	74 (77.9)	83 (80.6)	
Cause of death				0.859
Progression	28 (52.8)	15 (51.7)	13 (54.2)	
Else	25 (47.2)	14 (48.3)	11 (45.8)	

Values are presented as number (%).

*Using Fisher exact test.

BMI: body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status; PY: pack years; DM: diabetes mellitus; HF: heart failure; CRF: chronic renal failure; LC: liver cirrhosis; CVA: cerebrovascular disease; TB: tuberculosis; CTx: chemotherapy; EP: etoposide-cisplatin; EC: etoposide-carboplatin; RT: radiotherapy; CCRT: concurrent chemoradiotherapy; PCI: prophylactic cranial irradiation.

system. Factors analyzed included type of lung cancer, weight, height, body mass index, smoking history (pack-years [PY]), comorbidities (diabetes mellitus, heart failure, chronic renal failure, liver cirrhosis, cerebrovascular disease, and pulmonary tuberculosis), Eastern Cooperative Oncology Group (ECOG) performance status, stage at diagnosis, first chemotherapy

regimen (etoposide-cisplatin [EP] and etoposide-carboplatin [EC]), the sum of cycles, concurrent chemoradiotherapy (CCRT) and cause of death.

Patients were divided into two groups by age (≤ 65 years vs. >65 years) and extent of disease (LD vs. ED).

Eligible SCLC patients were ambulatory. They were newly

Table 3. Baseline characteristics (extensive disease small cell lung cancer)

Variable	Total	≤ 65 Years (n=70)	>65 Years (n=65)	p-value
BMI, kg/m ²				0.549
≤ 23	67 (49.6)	33 (47.1)	34 (52.3)	
>23	68 (50.4)	37 (52.9)	31 (47.7)	
ECOG PS				0.645
0,1	63 (46.7)	34 (48.6)	29 (44.6)	
2	72 (53.3)	36 (51.4)	36 (55.4)	
Smoking				0.499
Current or ex-smoker	117 (86.7)	62 (88.6)	55 (84.6)	
Non-smoker	18 (13.3)	8 (11.4)	10 (15.4)	
Smoking (PY)	40.0 (25.0–50.0)	30.0 (20.0–45.0)	40.0 (30.0–50.0)	0.008
Comorbidity				
DM	24 (17.8)	11 (15.7)	13 (20.0)	0.515
HF	0 (0)	0 (0)	0 (0)	
CRF	0 (0)	0 (0)	0 (0)	
LC	1 (0.7)	0 (0)	1 (1.5)	0.482*
CVA	1 (0.7)	0 (0)	1 (1.5)	0.482*
Inactive TB	16 (11.9)	7 (10)	9 (13.9)	0.490
First CTx regimen				<0.001
EP	78 (57.8)	53 (75.7)	25 (38.5)	
EC	57 (42.2)	17 (24.3)	40 (61.5)	
The sum of cycles				0.039
2–3	26 (19.3)	11 (15.7)	15 (23.1)	
≥ 4	109 (80.7)	59 (84.3)	50 (76.9)	
Thoracic RT (CCRT)				0.338
Yes	32 (23.7)	21 (30.0)	11 (16.9)	
PCI				0.091
Yes	36 (26.7)	23 (32.9)	13 (20.0)	
Progression of disease				0.128
Progression	15 (11.1)	5 (7.1)	10 (15.4)	
Non-progression	120 (88.9)	65 (92.9)	55 (84.6)	
Cause of death				0.016*
Progression		59 (98.3)	50 (86.2)	
Else	9 (7.6)	1 (1.7)	8 (13.8)	

*Using Fisher exact test.

BMI: body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status; PY: pack years; DM: diabetes mellitus; HF: heart failure; CRF: chronic renal failure; LC: liver cirrhosis; CVA: cerebrovascular disease; TB: tuberculosis; CTx: chemotherapy; EP: etoposide-cisplatin; EC: etoposide-carboplatin; RT: radiotherapy; CCRT: concurrent chemoradiotherapy; PCI: prophylactic cranial irradiation.

diagnosed of SCLC at tertiary hospital during this period. Patients had never been treated SCLC before. They had 0–2 in ECOG performance status. Patients aged ≤ 18 years were excluded. Primary end points is overall survival (OS). Secondary end points is progression-free survival (PFS).

3. Statistical analysis

Clinical factors in patients aged ≤ 65 years vs. >65 years and those with LD and ED were compared by Mann-Whitney U tests for continuous variables and chi-square tests or Fisher exact tests for categorical variables. OS and PFS were estimated by the Kaplan-Meier method, with results compared by log-rank tests. Risk factors for survival were determined by multivariable analysis using Cox's proportional hazard

regression model. Statistical analyses were performed using SAS ver. 9.4 (SAS Institute Inc., Cary, NC, USA) and R ver. 3.2.0 (Microsoft (R), Seattle, WA, USA). All p-values were two-sided statistical ($\alpha=0.05$), with p-values <0.05 considered statistically significant.

Results

The baseline characteristics of the 333 included patients are shown in Table 1. By age, 165 of these patients were ≤ 65 years old and 168 were >65 years old. Of the 333 patients with SCLC, 198 had LD, including 95 aged ≤ 65 and 103 aged >65 years, whereas 135 patients had ED, including 70 aged ≤ 65 and 65 aged >65 years. A comparison of the two age groups




Figure 1. (A, B) Subgroup analysis showed that overall survival (OS) was significantly longer in younger than in older patients with limited disease (LD) ($p=0.003$), but did not differ with age in extensive disease (ED) ($p=0.279$).




Figure 2. (A, B) Subgroup analysis showed that progression-free survival (PFS) was similar in all patients with limited disease (LD) ($p=0.336$) and extensive disease (ED) ($p=0.727$).

showed that younger patients were significantly more likely to receive EP than EC as first-line chemotherapy and were significantly more likely to undergo prophylactic cranial irradiation (PCI). The results showed that first-line chemotherapy with EP more frequent than with EC, ≥ 4 which is the sum of cycles and PCI performed more frequently in aged ≤ 65 than aged >65 years in LD-SCLC and ED-SCLC (Tables 2, 3). We divided the cause of death as disease progression and others. The death by disease progression was 137 (80.1%) and others was 34 (19.9%) (Table 1). And each percent of disease progression and others was not different in LD patients (Table 2). But death by disease progression were much more than others regardless of age in ED patients (Table 3). A comparison of survival outcomes (Figure 1A) showed that OS was significantly greater in younger than in older patients with LD-SCLC but did not differ in younger and older patients with ED (Figure 1B). PFS (Figure 2A, B) analysis showed that PFS was similar in younger and older patients with LD and ED.

Univariate analysis showed that older age, increased number of smoking (PY), fewer the sum of cycles (EC/EP) and absence of PCI were associated with significantly shorter OS. Multivariate analysis showed that older age and fewer than four of cycles were statistically independent predictors of shorter OS, significantly (Table 4). Univariate analysis showed that fewer the sum of cycles (EC/EP) and absence of CCRT

were associated with significantly shorter PFS. Multivariate analysis showed that fewer the sum of cycles (EC/EP), absence of CCRT and absence of PCI were statistically independent predictors of shorter PFS, significantly (Table 5).

Discussion

This study found that patients with LD-SCLC had a better prognosis when aged ≤ 65 than >65 years. However, another studies⁵⁻⁷ found that age was not significantly prognostic of survival in patients with LD-SCLC. This discrepancy may have been due to differences in patient populations, including ethnicity and comorbidity. By contrast, age was not associated with prognosis in patients with ED-SCLC.

Older patients are associated with decreased performance status and increased comorbidity. Therefore, survival rates were lower with advancing age in LD-SCLC⁸. Also, other study² announced that treatment led to a slightly increase of risk of death in patients with comorbidities in LD-SCLC. In ED-SCLC patients, OS was not different between two age groups. At diagnosis, the extension of disease were much larger regardless of age. Therefore, the prognosis have no difference by age in ED-SCLC patients.

Moreover, thoracic radiotherapy, CCRT, and platinum-

Table 4. Univariate and multivariate analyses of factors associated with OS in patients with limited disease

Variable	Univariate			Multivariate		
	Hazard ratio	95% Hazard ratio	p-value	Hazard ratio	95% Hazard ratio	p-value
Age (≤ 65 yr)	0.590	0.413–0.841	0.003	0.503	0.344–0.735	<0.001
BMI (>23)	0.782	0.553–1.107	0.166	-	-	-
ECOG PS (2)	1.026	0.566–1.860	0.933	-	-	-
Smoking (current or Ex)	0.685	0.439–1.070	0.096	-	-	-
PY	1.008	1.000–1.015	0.051	-	-	-
DM (+)	1.419	0.903–2.232	0.130	-	-	-
HF (+)	1	0.574–30.319	0.158	-	-	-
LC (+)	1.435	0.200–10.269	0.719	-	-	-
CVA (+)	0.553	0.176–1.740	0.311	-	-	-
Inactive TB (+)	0.880	0.461–1.680	0.699	-	-	-
The sums of cycles						
3	0.855	0.338–2.166	0.741	1.633	0.626–4.26	0.316
≥ 4	0.257	0.129–0.512	<0.001	0.242	0.12–0.487	<0.001
CCRT (no)	1.450	0.758–2.773	0.261	-	-	-
PCI (yes)	0.561	0.388–0.810	0.002	0.604	0.409–0.891	0.011
First CTx regimen (EP)	0.844	0.475–1.499	0.563	-	-	-

OS: overall survival; BMI: body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status; Ex: stop smoking now; PY: pack years; DM: diabetes mellitus; HF: heart failure; LC: liver cirrhosis; CVA: cerebrovascular disease; TB: tuberculosis; CCRT: concurrent chemoradiotherapy; PCI: prophylactic cranial irradiation; CTx: chemotherapy; EP: etoposide-carboplatin.

Table 5. Univariate and multivariate analyses of factors associated with PFS in patients with LD

Variable	Univariate			Multivariate		
	Hazard ratio	95% Hazard ratio	p-value	Hazard ratio	95% Hazard ratio	p-value
Age (≤ 65 yr)	0.856	0.624–1.175	0.337	-	-	-
BMI (>23)	0.951	0.693–1.304	0.754	-	-	-
ECOG PS (2)	0.816	0.452–1.473	0.500	-	-	-
Smoking (current or Ex)	0.565	0.373–0.855	0.007	0.612	0.395–0.948	0.028
PY	1.003	0.996–1.011	0.339	-	-	-
DM (+)	1.084	0.693–1.695	0.725	-	-	-
HF (+)	0.000	0.000	0.982	-	-	-
LC (+)	1.607	0.224–11.542	0.637	-	-	-
CVA (+)	0.544	0.201–1.471	0.230	-	-	-
Inactive TB (+)	0.987	0.558–1.747	0.965	-	-	-
The sums of cycles						-
3	0.227	0.075–0.684	0.008	0.827	0.269–2.54	0.740
≥ 4	0.161	0.072–0.360	<0.001	0.15	0.066–0.34	<0.001
CCRT (yes)	2.531	1.237–5.179	0.011	4.605	1.913–11.084	0.001
PCI (yes)	0.749	0.543–1.034	0.079	0.683	0.486–0.96	0.028
First CTx regimen (EP)	1.208	0.669–2.178	0.531	-	-	-

PFS: progression-free survival; LD: limited disease; BMI: body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status; Ex: stop smoking now; PY: pack years; DM: diabetes mellitus; HF: heart failure; LC: liver cirrhosis; CVA: cerebrovascular disease; TB: tuberculosis; CCRT: concurrent chemoradiotherapy; PCI: prophylactic cranial irradiation; CTx: chemotherapy; EP: etoposide-carboplatin.

based chemotherapy have been found to significantly improve survival⁹. Our results showed that younger age, PCI and increased the sum of cycles were associated with better prognosis, whereas CCRT and the first chemotherapy regimen were not. Although patients aged ≤ 65 years were treated more aggressively and had better prognosis than patients >65 years¹⁰, chemotherapy should not be withheld from older patients based solely on age. The survival of patients who receive chemotherapy is significantly longer than that of untreated patients, despite requiring frequent dose reductions for toxicity. Survival benefits are due to the effects of treatment and not to a selection bias in patients chosen for therapy¹¹.

This study had several limitations. It is a retrospective design and the performance at a single center. And we had better study about treatment plan considering biological age, performance status and patient's attitude.

This study showed that OS was significantly improved in younger than in older patients with LD-SCLC. But, age was not associated with prognosis in patients with ED-SCLC. Clinician will make a decision about treatment considering biological age. It is multiple concept including comorbidity index and tolerability for treatment.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

- Martini B. Lung cancer: epidemiology, prognosis and therapy. *Med Monatsschr Pharm* 2006;29:217-21.
- Aarts MJ, Aerts JG, van den Borne BE, Biesma B, Lemmens VE, Kloover JS. Comorbidity in patients with small-cell lung cancer: trends and prognostic impact. *Clin Lung Cancer* 2015;16:282-91.
- Shin SY, Lyu Y, Shin Y, Choi HJ, Park J, Kim WS, et al. Lessons learned from development of de-identification system for biomedical research in a Korean tertiary hospital. *Healthc Inform Res* 2013;19:102-9.
- Shin SY, Park YR, Shin Y, Choi HJ, Park J, Lyu Y, et al. A De-identification method for bilingual clinical texts of various note types. *J Korean Med Sci* 2015;30:7-15.
- Siu LL, Shepherd FA, Murray N, Feld R, Pater J, Zee B. Influence of age on the treatment of limited-stage small-cell lung cancer. *J Clin Oncol* 1996;14:821-8.
- Gridelli C, Casaluce F, Sgambato A, Monaco F, Guida C. Treat-

- ment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that's the question. *Transl Lung Cancer Res* 2016;5:150-4.
7. Rossi A, Maione P, Colantuoni G, Guerriero C, Ferrara C, Del Gaizo F, et al. Treatment of small cell lung cancer in the elderly. *Oncologist* 2005;10:399-411.
 8. Ludbrook JJ, Truong PT, MacNeil MV, Lesperance M, Webber A, Joe H, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. *Int J Radiat Oncol Biol Phys* 2003;55:1321-30.
 9. Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z, et al. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. *Lung Cancer* 2010;67:221-6.
 10. Radzikowska E, Roszkowski K, Glaz P. Lung cancer in patients under 50 years old. *Lung Cancer* 2001;33:203-11.
 11. Shepherd FA, Amdemichael E, Evans WK, Chalvardjian P, Hogg-Johnson S, Coates R, et al. Treatment of small cell lung cancer in the elderly. *J Am Geriatr Soc* 1994;42:64-70.